SNSarah C. Nyirjesy

Sarah C. Nyirjesy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah C. Nyirjesy has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Allen L. Feng

    Harvard Medical School, Boston, USA; Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Boston, USA

    2 shared publications
  • Emilie C.M. de Groot

    2 shared publications
  • Jeremy D. Richmon

    Department of Otolaryngology—Head and Neck Surgery Massachusetts Eye and Ear and Harvard Medical School Boston Massachusetts USA

    2 shared publications
  • Kyle K. VanKoevering

    Department of Otolaryngology‐Head & Neck Surgery The Ohio State University Wexner Medical Center Columbus Ohio USA

    2 shared publications
  • Kyle K. VanKoevering

    Department of Otolaryngology-Head and Neck Surgery, The James Cancer Hospital/Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA

    2 shared publications
  • Margaret A. Heller

    Department of Otolaryngology – Head and Neck Surgery The Ohio State University Wexner Medical Center Columbus Ohio USA

    2 shared publications

Latest Publications

  • Accuracy of radiographic nodal counts in HPV-positive oropharyngeal cancer and impact on treatment

    by Sarah C. Nyirjesy, Emilie C.M. de Groot, Yuh-Shin Chang, Laura V. Romo, Manuel Patino Galindo, Emil J. Barkovich, Stacy Hooker, Lori J. Wirth, Jeremy D. Richmon


  • Incidence of HPV-independent second primary malignancies following treatment of HPV-associated malignancy

    by Sarah C. Nyirjesy, Yana Al-Inaya, Selena Zhang, Omar A. Karadaghy, Derrick T. Lin, Daniel G. Deschler, Allen L. Feng, Mark A. Varvares, Adam S. Fisch, Daniel L. Faden, et al.

  • Open Access

    Evaluating Listening Effort in Unilateral, Bimodal, and Bilateral Cochlear Implant Users

    by Sarah C. Nyirjesy, Jessica H. Lewis, Diana Hallak, Sara Conroy, Aaron C. Moberly, Terrin N. Tamati

    Objective: Evaluate listening effort (LE) in unilateral, bilateral, and bimodal cochlear implant (CI) users. Establish an easy‐to‐implement task of LE that could be useful for clinical decision making.Study Design: Prospective cohort study.Setting: Tertiary neurotology center.Methods: The Sentence Final Word Identification and Recall Task, an established measure of LE, was modified to include challenging listening conditions (multitalker babble, gender, and emotional variation; test), in addition to single‐talker sentences (control). Participants listened to lists of sentences in each condition and recalled the last word of each sentence. LE was quantified by percentage of words correctly recalled and was compared across conditions, across CI groups, and within subjects (best aided vs monaural).Results: A total of 24 adults between the ages of 37 and 82 years enrolled, including 4 unilateral CI users (CI), 10 bilateral CI users (CICI), and 10 bimodal CI users (CIHA). Task condition impacted LE (P < .001), but hearing configuration and listener group did not (P = .90). Working memory capacity and contralateral hearing contributed to individual performance.Conclusion: This study adds to the growing body of literature on LE in challenging listening conditions for CI users and demonstrates feasibility of a simple behavioral task that could be implemented clinically to assess LE. This study also highlights the potential benefits of bimodal hearing and individual hearing and cognitive factors in understanding individual differences in performance, which will be evaluated through further research.


  • Higher Computed Tomography (CT) Scan Resolution Improves Accuracy of Patient-specific Mandibular Models When Compared to Cadaveric Gold Standard

    by Maariyah Ahmed, Luigi E. Melaragno, Sarah C. Nyirjesy, Natalia von Windheim, Rachel Fenberg, Rachel Herster, Alexandra Sheldon, Katherine Binzel, Michael V. Knopp, Edward D. Herderick, et al.


  • Open Access

    Successful Early Neovascularization in Composite Tracheal Grafts

    by Sarah C. Nyirjesy, Jane Yu, Sayali Dharmadhikari, Lumei Liu, Maxwell Bergman, Zheng Hong Tan, Kyle K. VanKoevering, Tendy Chiang

    Objective: Long‐segment tracheal defects require tissue replacement for successful reconstruction. Rapid revascularization is imperative to maintain graft function. We previously showed that partially decellularized tracheal grafts (PDTG) and composite tracheal grafts (CTG; PDTG supported by a 3‐dimensionally printed external splint) regenerate respiratory epithelium and may support the regeneration of endothelial cells (CD31+). However, the capability of graft endothelial cells to organize or contribute to tracheal revascularization remains unclear. In this study, we quantified endothelial cells (CD31+) and neovessel formation in PDTG and CTG. We hypothesize that PDTG and CTG support tracheal neovascularization to a similar extent as surgical (syngeneic tracheal graft [STG]) and native trachea (NT) controls.Study Design: The animal study, a randomized control trial.Setting: Center for Regenerative Medicine, Nationwide Children's Hospital.Methods: PDTG was created via an established decellularization protocol. Segmental tracheal reconstruction was performed with STG, PDTG, or CTG using a mouse microsurgical model. NT was used as a nonsurgical control. At 1 month, mice were euthanized, grafts harvested, sectioned, and stained with CD31 and hematoxylin and eosin. Neovessel formation was quantified by the number of formed blood vessels in the lamina propria and vessel size (vessel/graft area, mm2).Results: Decellularization eliminated all endothelial cells and there were no perfused vessels at implantation. At 1 month, PDTG and CTG supported neovessel formation with tubular vessels lined with endothelial cells. There was no difference in the number or size of vessels compared to controls.Conclusion: PDTG and CTG support tracheal endothelial cell regeneration and neovessel formation. Future directions to assess the function, kinetics, and distribution of graft neovessels are needed.


  • Open Access

    Hypothyroidism as an Independent Predictor of 30‐day Readmission in Head and Neck Cancer Patients

    by Sarah C. Nyirjesy, Songzhu Zhao, Ryan Judd, Hilary McCrary, Hannah N. Kuhar, Janice L. Farlow, Nolan B. Seim, James W. Rocco, Stephen Y. Kang, Catherine T. Haring

    Objectives: To define the role of hypothyroidism and other risk factors for unplanned readmissions after surgery for head and neck cancer.Study Design: Retrospective cohort study.Methods: The Nationwide Readmission Database (NRD) was used to identify patients who underwent surgery for mucosal head and neck cancer (oral cavity, oropharynx, larynx, and hypopharynx) between 2010 and 2017. Univariate and multivariate logistic regression were performed to determine patient, tumor, and hospital related risk factors for 30‐day readmission. Readmitted patients were stratified by preoperative diagnosis of hypothyroidism to compare readmission characteristics.Results: For the 131,013 patients who met inclusion criteria, the readmission rate was 15.9%. Overall, 11.91% of patients had a preoperative diagnosis of hypothyroidism. After controlling for other variables, patients with a preoperative diagnosis of hypothyroidism had 12.2% higher odds of readmission compared to those without hypothyroidism (OR: 1.12, 1.03–1.22, p = 0.008). Patients with hypothyroidism had different reasons for readmission, including higher rates of wound dehiscence, fistula, infection, and electrolyte imbalance. Among readmitted patients, the length of stay for index admission (mean 10.5 days vs. 9.2 days, p < 0.001), readmission (mean 7.0 vs. 6.6 days, p = 0.05), and total hospital charge were higher for hypothyroid patients ($137,742 vs. $119,831, p < 0.001).Conclusion: Hypothyroidism is an independent risk factor for 30‐day readmission following head and neck cancer resection. Furthermore, hypothyroid patients are more likely to be readmitted for wound complications, infection, and electrolyte imbalance. Targeted interventions should be considered for hypothyroid patients to decrease readmission rates and associated patient morbidity, potentially leading to earlier initiation of adjuvant treatment.Level of Evidence: 3 Laryngoscope, 133:2988–2998, 2023


  • Open Access

    Response to induction chemotherapy in sinonasal malignancies: A single‐institutional experience

    by Sarah C. Nyirjesy, Rachel Fenberg, Margaret A. Heller, Ryan T. Judd, Michael M. Li, Brandon Koch, Marcelo Bonomi, Ricardo L. Carrau, Kyle K. VanKoevering

    Background: Sinonasal malignancy (SNM) is a heterogeneous group of diseases for which induction chemotherapy (IC) may reduce tumor burden. The purpose of this study was to characterize the response to IC in SNM as a prognostic factor through its effect on survival.Methods: Retrospective cohort of patients undergoing IC for SNM between 2010 and 2019 at our quaternary referral center.Results: Forty‐two patients with advanced SNM were included in the analysis. Patients with a favorable response to IC had higher survival rates than those who had an unfavorable response (5‐year OS: 66.8% vs. 9.7%; p < 0.001; PFS: 56.8% vs. 0%; p < 0.001).Conclusions: Response to IC in our patient cohort was a prognostic indicator of overall response to treatment. Further elucidation of predictors of response is needed for appropriate patient selection.


  • Open Access

    Superior Laryngeal Nerve Block Response Rates in 54 Neurogenic Cough Patients

    by Nicholas Talbot, Margaret Heller, Sarah Nyirjesy, Brandon Kim, Brad DeSilva, Laura Matrka

    Objective: Neurogenic cough related to hypersensitivity of the internal branch of the superior laryngeal nerve (SLN) is often treated with neuromodulating medications, which can cause considerable side effects. An alternative therapy is steroid and local anesthetic injection of the SLN (“SLN block”), initially proposed to benefit those with lateralizing symptoms (tenderness over the thyrohyoid membrane or unilateral cough source). Our objectives are to determine if SLN block produces subjective symptomatic improvements and if repeat injections further improve symptoms, and evaluate clinical factors potentially predictive of response.Methods: Retrospective chart review of 54 patients receiving SLN blocks at a tertiary medical academic center from January 2010 to June 2020. Medical history and anticipated predictors of positive response, including stigmata of laryngeal hypersensitivity, were recorded. Outcomes included symptomatic response, number of injections required, and side effects. Response was defined subjectively by asking patients whether the injection was beneficial and objectively by using CSI scores.Results: Fifty‐four patients met the inclusion criteria. Thirty‐eight patients (70.4%) endorsed improvement. No variables were identified as positive predictors of response. Thirty‐two of the 38 (84.2%) endorsed improvement after one injection. Six of 15 (40%) patients who failed the first injection had positive response to the second. No significant side effects were reported.Conclusion: No localizing symptoms, specific cough features, or aspects of the medical history helped predict response, suggesting that a broader range of patients may be offered the intervention. The majority of patients reported symptomatic improvement and repeat injections may benefit patients with initial nonresponse.Level of Evidence: 4 Laryngoscope, 133:2647–2653, 2023


  • Modifiable risk factors for oral cavity cancer in non-smokers: A systematic review and meta-analysis

    by Margaret A. Heller, Sarah C. Nyirjesy, Robert Balsiger, Nicholas Talbot, Kyle K. VanKoevering, Catherine T. Haring, Matthew O. Old, Stephen Y. Kang, Nolan B. Seim